Freedom Investment Management Inc. Has $773,000 Position in Haleon plc (NYSE:HLN)

Freedom Investment Management Inc. trimmed its holdings in shares of Haleon plc (NYSE:HLN) by 21.0% in the third quarter, Holdings Channel.com reports. The fund owned 73,069 shares of the company’s stock after selling 19,367 shares during the quarter. Freedom Investment Management Inc.’s holdings in Haleon were worth $773,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in HLN. B. Riley Wealth Advisors Inc. lifted its stake in Haleon by 23.2% during the first quarter. B. Riley Wealth Advisors Inc. now owns 29,324 shares of the company’s stock worth $246,000 after purchasing an additional 5,519 shares during the period. Atria Investments Inc lifted its position in shares of Haleon by 5.7% during the 1st quarter. Atria Investments Inc now owns 181,557 shares of the company’s stock worth $1,541,000 after buying an additional 9,746 shares during the period. Cetera Investment Advisers boosted its stake in Haleon by 106.3% in the 1st quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock valued at $1,985,000 after buying an additional 120,447 shares in the last quarter. Cetera Advisors LLC grew its position in Haleon by 524.3% in the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock valued at $696,000 after acquiring an additional 68,857 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in Haleon by 13.8% during the first quarter. EverSource Wealth Advisors LLC now owns 16,204 shares of the company’s stock worth $138,000 after acquiring an additional 1,962 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HLN shares. UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Morgan Stanley raised their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, Berenberg Bank started coverage on Haleon in a report on Tuesday, August 6th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Stock Up 1.4 %

Shares of NYSE HLN opened at $9.72 on Friday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The firm’s 50-day simple moving average is $9.95 and its 200 day simple moving average is $9.41. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The company has a market cap of $44.00 billion, a price-to-earnings ratio of 28.59, a price-to-earnings-growth ratio of 2.89 and a beta of 0.30.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.